Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 99-102, April 2010

Stereotactic fractionated radiotherapy for Klatskin tumours

  • Felix Momm

      Affiliations

    • University Hospital Freiburg, Department of Radiation Oncology, Freiburg i. Br., Germany
    • Corresponding Author InformationCorresponding author. Address: Universitätsklinikum Freiburg, Klinik für Strahlenheilkunde, Robert-Koch-Str. 3, 79106 Freiburg, Germany.
  • ,
  • Eva Schubert

      Affiliations

    • University Hospital Freiburg, Department of Radiation Oncology, Freiburg i. Br., Germany
  • ,
  • Karl Henne

      Affiliations

    • University Hospital Freiburg, Department of Radiation Oncology, Freiburg i. Br., Germany
  • ,
  • Norbert Hodapp

      Affiliations

    • University Hospital Freiburg, Department of Radiation Oncology, Freiburg i. Br., Germany
  • ,
  • Hermann Frommhold

      Affiliations

    • University Hospital Freiburg, Department of Radiation Oncology, Freiburg i. Br., Germany
  • ,
  • Jan Harder

      Affiliations

    • University Hospital Freiburg, Department of Gastroenterology and Hepatology, Freiburg i. Br., Germany
  • ,
  • Anca-Ligia Grosu

      Affiliations

    • University Hospital Freiburg, Department of Radiation Oncology, Freiburg i. Br., Germany
  • ,
  • Gerhild Becker

      Affiliations

    • University Hospital Freiburg, Department of Gastroenterology and Hepatology, Freiburg i. Br., Germany

Received 30 November 2009; received in revised form 24 February 2010; accepted 7 March 2010. published online 29 March 2010.

Abstract 

Background and purpose

In spite of various efforts perihilar cholangiocellular carcinoma (Klatskin tumour) has still a bad prognosis. The treatment of patients with inoperable Klatskin tumours by stereotactic fractionated radiotherapy (SFRT) was analysed retrospectively.

Patients, methods and materials

In our department 13 patients were treated for Klatskin tumours by SFRT (32–56Gy, 3×4Gy/week) from 1998 to 2008. The treatment technique was developed from stereotactic body frame radiotherapy to image guided (IGRT) stereotactic radiotherapy with control of patient positioning by cone beam computer tomography (CBCT). 6/13 patients received additional chemotherapy before or after SFRT.

Results

A median survival of 33.5 (6.6–60.4) months after diagnosis was reached by SFRT. The median time of freedom from tumour progression was 32.5 (6.1–60.4, last patient died without tumour progression) months. The therapy was tolerated very well. Nausea was the most common side effect. 5/13 patients suffered from recurrent cholangitis caused and enhanced by the primary tumour and drainages or stents in the bile ducts.

Conclusions

In the context of reaching local control being still the main problem of Klatskin tumour patients, SFRT seems to be a very promising method for the treatment of these tumours.

Keywords: Klatskin tumour, Cholangiocellular carcinoma, Stereotactic fractionated radiotherapy, Extracranial stereotactic radiotherapy, Cone beam CT

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(10)00168-4

doi:10.1016/j.radonc.2010.03.013

Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 99-102, April 2010